McGuire P K, Jones P, Harvey I, Williams M, McGuffin P, Murray R M
Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London, UK.
Schizophr Res. 1995 May;15(3):277-81. doi: 10.1016/0920-9964(94)00053-b.
Twenty-three patients admitted with acute psychosis who were cannabis positive on urinary screening were each matched, with respect to sex, with two psychotic controls who screened negatively for all substances. The lifetime morbid risk of psychiatric disorder was estimated among the first degree relatives of cases and controls, using RDC-FH criteria to define diagnoses, and Weinberg's shorter method of age correction. The cases had a significantly greater familial morbid risk of schizophrenia (7.1%) than the controls (0.7%), while the risks of other psychoses, and of non-psychotic conditions were similar. The same pattern of familial risk was evident when the analysis was restricted to patients with DSM-III schizophrenia. The data suggest that the development or recurrence of acute psychosis in the context of cannabis use may be associated with a genetic predisposition to schizophrenia.
23名因急性精神病入院且尿液筛查大麻呈阳性的患者，在性别方面，每人与两名所有物质筛查均为阴性的精神病对照组进行匹配。采用RDC - FH标准定义诊断，并使用温伯格较短的年龄校正方法，估计病例组和对照组一级亲属的终身精神疾病患病风险。病例组精神分裂症的家族患病风险（7.1%）显著高于对照组（0.7%），而其他精神病和非精神病疾病的风险相似。当分析仅限于符合DSM - III精神分裂症标准的患者时，家族风险模式相同。数据表明，在使用大麻的情况下急性精神病的发生或复发可能与精神分裂症的遗传易感性有关。
